Melatonin Use for COVID-19 Infection: Time to Diversify the Treatment Portfolio

RUSSEL J. REITER; RAMASWAMY SHARMA; DUN XIAN TAN; FEDOR SIMKO; WALTER MANUCHA; SERGIO ROSALES-CORRAL; DANIEL P. CARDINALI

JOURNAL OF MEDICAL VIROLOGY

WILEY-LISS, DIV JOHN WILEY & SONS INC

Lugar: New York; Año: 2022 vol. 94 p. 2928 - 2930

0146-6615

No single treatment will eliminate the COVID-19 pandemic. It is imperative that all available tactics and medications be used to overcome this disease, although it will probably never totally disappear. Melatonin is a very inexpensive molecule so it is affordable in all areas of the world, it does not require refrigeration and it has a very long shelf-life. Melatonin has no substantial side effects even at extremely high doses, no overdose has ever been achieved, and it can be self-administered via several routes. Considering its efficacy in both experimental studies and clinical trials, the portfolio of medications used to a curtail a COVID-19 infection should clearly include melatonin. Since melatonin inhibits many types of viruses, it should also be considered a potential treatment of Ebola, Zeka, and hantavirus infections.